ASTELLAS PHARMA UNSP/ADR - ALPMY STOCK NEWS

Welcome to our dedicated page for ASTELLAS PHARMA UNSP/ADR news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on ASTELLAS PHARMA UNSP/ADR stock.

Astellas Pharma Inc. is a global pharmaceutical company with operations in over 70 countries. The company focuses on creating innovative drugs to treat diseases with high unmet medical needs by emphasizing Biology and Modality. Beyond traditional pharmaceuticals, Astellas is exploring Rx+® healthcare solutions in collaboration with cutting-edge technology partners. Astellas recently opened a state-of-the-art West Coast Innovation Center in South San Francisco, enhancing its commitment to biotech innovation.

The company is actively involved in research and development, with recent advancements in cancer therapies like zolbetuximab, a monoclonal antibody targeting gastric and gastroesophageal cancers. Astellas' collaborations with Pfizer and Merck, as well as YASKAWA Electric Corporation, demonstrate its commitment to pioneering research and creating new treatment paradigms by integrating pharmaceutical and robotics technologies.

05/08/2024 11:39 AM

News

Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor

Rhea-AI Summary

Astellas Pharma Inc. unveiled a new $90 million West Coast Innovation Center in the South San Francisco Biotech Corridor. The 154,000 square-foot lab and office facility serves as a central location for Astellas' West Coast cell and gene therapy research and business development operations. The center aims to enhance collaboration, productivity, and innovation to deliver innovative treatments and value to patients worldwide.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.19%

Tags

04/23/2024 07:30 PM

News

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Rhea-AI Summary

Astellas Pharma's XTANDI (Enzalutamide) receives European Commission approval for use in additional recurrent early prostate cancer treatment setting, making it the first novel hormone therapy available for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the EU. The approval is based on positive Phase 3 EMBARK study results, showing XTANDI alone or in combination with leuprolide reduces the risk of metastasis or death. The European Association of Urology updated their treatment guidelines to include enzalutamide for men with high-risk BCR nmHSPC, filling a treatment gap in this patient population.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.21%

Tags

04/22/2024 04:10 AM

News

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

Rhea-AI Summary

Takeda, Astellas, and Sumitomo Mitsui Banking have announced a master agreement to establish a joint venture company dedicated to the incubation of early drug discovery programs in Japan. The new company aims to advance innovative drug discovery programs, foster entrepreneurship, and create start-up companies to unleash the potential of the drug discovery ecosystem in Japan.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.32%

Tags

03/28/2024 11:00 AM

News

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Rhea-AI Summary

Astellas Pharma Inc. announces the acceptance of the sBLA for enfortumab vedotin with KEYTRUDA as a combination therapy for first-line treatment of urothelial cancer in China, potentially offering an alternative to platinum-containing chemotherapy. The pivotal trial results show significant improvements in overall and progression-free survival, potentially changing the treatment paradigm for this life-threatening condition.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.74%

Tags

03/26/2024 08:30 AM

News

Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Rhea-AI Summary

Iveric Bio, An Astellas Company, receives a permanent J-code (J2782) effective April 1, 2024, for IZERVAY™, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The J-code will streamline billing and reimbursement processes, increasing patient access to the FDA-approved treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.47%

Tags

03/26/2024 08:00 AM

News

Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer

Rhea-AI Summary

Astellas Pharma Inc. announces MHLW approval of VYLOY for gastric cancer treatment, making it the first CLDN18.2-targeted therapy globally. Approval based on successful Phase 3 trials showing significant improvement in progression-free and overall survival rates.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.47%

Tags

03/22/2024 08:00 AM

News

Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Rhea-AI Summary

Astellas Pharma Inc. announced a positive CHMP opinion recommending approval of XTANDI for the treatment of high-risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patients in the EU. This decision could make XTANDI the first NHT treatment available for this patient population in the EU by June 2024. The positive opinion is based on Phase 3 EMBARK trial results, indicating potential approval for XTANDI in the EU and other regions beyond the US, where it was already approved for a similar indication.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.45%

Tags

03/11/2024 09:00 AM

News

FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children

Rhea-AI Summary

Astellas Pharma US, Inc. receives FDA approval for CRESEMBA to treat serious fungal infections in children, granting seven years of market exclusivity. The drug is the first to be approved for pediatric patients as young as one, providing a vital treatment option for rare and life-threatening infections.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.54%

Tags

03/03/2024 06:31 PM

News

Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Rhea-AI Summary

Astellas Pharma Inc. announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, a nonhormonal compound for treating vasomotor symptoms in Japanese women. The company aims to provide a novel treatment option for menopausal symptoms.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.63%

Tags

02/15/2024 06:30 PM

News

PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer

Rhea-AI Summary

Astellas Pharma Inc. receives priority review for PADCEV™ and KEYTRUDA® combination therapy for urothelial cancer treatment, based on positive Phase 3 trial results.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.45%

Tags

FAQ

What is the current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY)?

The current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY) is $10.09 as of November 22, 2024.

What is the market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY)?

The market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY) is approximately 19.1B.

What is Astellas Pharma Inc. known for?

Astellas Pharma Inc. is recognized as a leading global pharmaceutical company operating in over 70 countries, focusing on developing innovative drugs for diseases with high unmet medical needs.

What recent achievements has Astellas Pharma Inc. made?

Astellas recently inaugurated a modern West Coast Innovation Center in South San Francisco, enhancing its presence in the biotech ecosystem.

What is zolbetuximab, and why is it significant?

Zolbetuximab is an investigational monoclonal antibody aimed at treating gastric and gastroesophageal cancers and is a testament to Astellas' commitment to pioneering cancer therapies.

How does Astellas collaborate with other companies like Pfizer, Merck, and YASKAWA Electric Corporation?

Astellas collaborates with Pfizer, Merck, and YASKAWA Electric Corporation to advance research and development in innovative treatments through partnerships that integrate pharmaceutical and robotics technologies.

What is Astellas Pharma Inc.'s focus beyond traditional pharmaceuticals?

Astellas is exploring Rx+® healthcare solutions with cutting-edge technology partners, aiming to create innovative treatment approaches beyond traditional pharmaceuticals.